34 results
8-K
EX-99.1
SAGE
Sage Therapeutics Inc
7 Aug 23
Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
6:45am
, specifically from the cohort of patients (n=277) that rolled over into the SHORELINE Study from the CORAL Study. In this cohort, the adverse event
8-K
EX-99.1
SAGE
Sage Therapeutics Inc
6 Dec 22
Other Events
6:51am
, and CORAL Studies). The NEST program includes two studies of zuranolone in adult women with PPD (ROBIN and SKYLARK Studies).
Zuranolone was granted … studies of zuranolone in people with MDD (MDD-201B, MOUNTAIN, SHORELINE, WATERFALL, and CORAL Studies). The NEST program includes two placebo-controlled
8-K
EX-99.1
qgms1rc x7
8 Nov 22
Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
6:45am
8-K
EX-99.1
whachrz5jax7
1 Jun 22
Other Events
7:16am
8-K
EX-99.1
fsyx2ae 39yh
3 May 22
Sage Therapeutics Announces First Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
6:45am
8-K
EX-99.1
9s847w81
24 Feb 22
Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business Progress
6:45am
8-K
e3rycjr kgfmgf
16 Feb 22
Other Events
7:00am
8-K
EX-99.1
caemiyeuz0m3w5 pn
16 Feb 22
Other Events
7:00am
8-K
EX-99.1
ziz9cxg6 tol2
10 Jan 22
Regulation FD Disclosure
7:31am
8-K
EX-99.1
qf5hs
1 Dec 21
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
7:00am
8-K
EX-99.1
bg9v7pru
2 Nov 21
Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
7:30am
8-K
EX-99.1
nrzgw36holmo98ua4
19 Oct 21
Other Events
8:01am